Skip to main content
. 2022 Sep 21;62(5):1851–1859. doi: 10.1093/rheumatology/keac522

Figure 4.

Figure 4.

ASDAS-CRP. (A) Change from baseline, (B) disease activity in the brodalumab group and (C) disease activity in the placebo group. ASDAS-CRP: AS Disease Activity Score using CRP; LS: least squares